Nuveen Asset Management, LLC Adma Biologics, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 6,577,877 shares of ADMA stock, worth $117 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

6,577,877

Previous 8,925,138 26.3%

Holding current value

$117 Million

Previous $99.8 Million 31.78%

% of portfolio

0.04%

Previous 0.03%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$11.21 - $20.03 $26.3 Million - $47 Million	-2,347,261 Reduced 26.3%	6,577,877 $131 Million
Q2 2024 Aug 09, 2024	SELL	$5.98 - $11.18 $9.19 Million - $17.2 Million	-1,536,238 Reduced 14.68%	8,925,138 $99.8 Million
Q1 2024 May 13, 2024	SELL	$4.4 - $6.74 $3.93 Million - $6.03 Million	-894,101 Reduced 7.87%	10,461,376 $69 Million
Q4 2023 Feb 14, 2024	BUY	$3.08 - $4.52 $2.06 Million - $3.03 Million	669,543 Added 6.27%	11,355,477 $51.3 Million
Q3 2023 Nov 14, 2023	BUY	$3.47 - $4.61 $7.38 Million - $9.8 Million	2,126,797 Added 24.85%	10,685,934 $38.3 Million
Q2 2023 Aug 14, 2023	SELL	$3.12 - $4.22 $1.48 Million - $2 Million	-473,176 Reduced 5.24%	8,559,137 $31.6 Million
Q1 2023 May 15, 2023	BUY	$3.01 - $3.87 $4.45 Million - $5.73 Million	1,479,806 Added 19.59%	9,032,313 $29.9 Million
Q4 2022 Feb 14, 2023	SELL	$2.47 - $3.88 $2.84 Million - $4.47 Million	-1,151,226 Reduced 13.23%	7,552,507 $29.3 Million
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $3.13 Million - $4.41 Million	1,541,544 Added 21.52%	8,703,733 $21.2 Million
Q2 2022 Aug 15, 2022	SELL	$1.43 - $2.2 $618,833 - $952,052	-432,751 Reduced 5.7%	7,162,189 $14.2 Million
Q1 2022 May 16, 2022	SELL	$1.28 - $1.83 $3.86 Million - $5.52 Million	-3,017,660 Reduced 28.43%	7,594,940 $11.8 Million
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.66 $4.06 Million - $6.19 Million	3,727,960 Added 54.15%	10,612,600 $15 Million
Q3 2021 Nov 12, 2021	BUY	$1.13 - $1.65 $1.11 Million - $1.62 Million	980,981 Added 16.62%	6,884,640 $7.78 Million
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.07 $1.29 Million - $1.77 Million	-855,303 Reduced 12.65%	5,903,659 $9.45 Million
Q1 2021 May 17, 2021	BUY	$1.67 - $2.95 $10.9 Million - $19.2 Million	6,502,025 Added 2530.59%	6,758,962 $11.9 Million
Q4 2020 Feb 16, 2021	BUY	$1.8 - $2.56 $2,532 - $3,601	1,407 Added 0.55%	256,937 $501,000
Q3 2020 Nov 16, 2020	SELL	$2.04 - $3.74 $243,196 - $445,860	-119,214 Reduced 31.81%	255,530 $611,000
Q2 2020 Aug 14, 2020	SELL	$2.42 - $3.29 $933,713 - $1.27 Million	-385,832 Reduced 50.73%	374,744 $1.1 Million
Q1 2020 May 14, 2020	BUY	$1.5 - $4.59 $722,814 - $2.21 Million	481,876 Added 172.9%	760,576 $2.19 Million
Q4 2019 Feb 14, 2020	BUY	$3.89 - $5.15 $563,711 - $746,301	144,913 Added 108.32%	278,700 $1.12 Million
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $206,370 - $348,695	64,693 Added 93.63%	133,787 $595,000
Q2 2019 Aug 15, 2019	BUY	$3.52 - $5.24 $243,210 - $362,052	69,094 New	69,094 $268,000

Others Institutions Holding ADMA

# of Institutions

319

Shares Held

184M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.48B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Adma Biologics, Inc. Transaction History